The impact of infliximab induction therapy on mucosal healing and clinical remission in Polish pediatric patients with moderate-to-severe Crohn's disease.
about
The Role of MR Enterography in Assessing Crohn's Disease Activity and Treatment ResponseClinical use and mechanisms of infliximab treatment on inflammatory bowel disease: a recent updateExperience with biosimilar infliximab (CT-P13) in paediatric patients with inflammatory bowel diseasesSafety profile of biologic therapy in Polish paediatric patients with Crohn's disease.Balancing and communicating the risks and benefits of biologics in pediatric inflammatory bowel diseaseLong-term Efficacy and Safety of Adalimumab in Pediatric Patients with Crohn's DiseaseAdvances in the medical management of paediatric IBD.Role of epithelial cells in the pathogenesis and treatment of inflammatory bowel disease.Adalimumab for endoscopic and histopathological mucosal healing in paediatric patients with moderate to severe Crohn's disease.The impact of induction therapy with three doses of infliximab on deep histological healing in paediatric patients with active Crohn's disease.Looking Beyond Mucosal Healing: Effect of Biologic Therapy on Transmural Healing in Pediatric Crohn's Disease.Exclusive Enteral Nutrition versus Infliximab in Inducing Therapy of Pediatric Crohn's Disease.Early Biologic Treatment in Pediatric Crohn's Disease: Catching the Therapeutic Window of Opportunity in Early Disease by Treat-to-Target.Profile of infliximab in the treatment of pediatric Crohn's disease.Risks and Benefits of Mucosal Healing With Combined Immunosuppression in Paediatric Crohn's Disease: A Complex Topic That Needs Careful Evaluation.
P2860
Q26773129-46C96A61-AD96-4DF3-B7BB-96892930634AQ26994776-A783E253-2B99-4C4C-9C5C-70925862CC72Q28066776-38A02CD7-0296-4525-B03A-D038EE41B5B8Q36167373-3BE01E3F-7084-4C2B-9FBB-8ADADD18FB84Q37609746-C34C425D-418E-4F19-B392-2AAECCAFF542Q37656048-A956826C-76EA-4228-BF94-240D245FB6ADQ38130044-E3DAB7A8-2765-4A8B-8033-BB84FC580AC5Q38542147-944BE1C4-05FC-4DE4-9D01-E3E8EDE0C4AAQ38880732-B00F53B8-38F4-4696-9A26-51EFCE8785F1Q39314651-25491DA9-472B-407A-AB92-0CDFD8B8B657Q39419352-DDF35FDD-1F3A-40B4-B617-27DC037A73C0Q41452217-E03932BB-99CD-468C-BC00-81EAC017947BQ48518781-8FD5DD0E-BD4D-4AC5-B850-B13921A9F690Q49165025-C2FEA08E-711C-4E9C-AFAD-9AB004853693Q52769725-B12DD097-EA1D-4588-8D61-2C978AF0AB07
P2860
The impact of infliximab induction therapy on mucosal healing and clinical remission in Polish pediatric patients with moderate-to-severe Crohn's disease.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
The impact of infliximab induc ...... ate-to-severe Crohn's disease.
@en
The impact of infliximab induc ...... ate-to-severe Crohn's disease.
@nl
type
label
The impact of infliximab induc ...... ate-to-severe Crohn's disease.
@en
The impact of infliximab induc ...... ate-to-severe Crohn's disease.
@nl
prefLabel
The impact of infliximab induc ...... ate-to-severe Crohn's disease.
@en
The impact of infliximab induc ...... ate-to-severe Crohn's disease.
@nl
P2093
P50
P1476
The impact of infliximab induc ...... ate-to-severe Crohn's disease.
@en
P2093
Agnieszka Wegner
Jarosław Kierkus
Jozef Ryzko
Maciej Dadalski
Marek Woynarowski
Monika Gorczewska
P304
P356
10.1097/MEG.0B013E32835159F2
P577
2012-05-01T00:00:00Z